Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime vs Diclophenac for Post-ERCP Pancreatitis
NCT01784445Phase 4Completed
- Sponsor
- Clinical Hospital Center Rijeka
- Start
- Jun 2013
- Primary completion
- Sep 2014
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), sponsored by Clinical Hospital Center Rijeka. Started Jun 2013; status: completed.
02
Drugs
ceftazidime
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT01784445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01784445.